{"id":"W4381377916","doi":"10.2337/db23-25-lb","title":"25-LB: Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy","year":2023,"lang":"en","type":"article","venue":"Diabetes","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Placebo; Medicine; Clinical endpoint; Diabetic retinopathy; Rash; Internal medicine; Adverse effect; Clinical trial; Endocrinology; Diabetes mellitus; Alternative medicine","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008618002,0.000949735,0.0009115162,0.0003421757,0.0002082078,0.0005506407,0.0004641661,0.0008602902,0.003957121],"category_scores_gemma":[0.0005265943,0.0002794581,0.0006621819,0.0001793899,0.0003984472,0.000427575,0.000202991,0.00139103,0.000645904],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003291172,"about_ca_system_score_gemma":0.0004382749,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006050757,"about_ca_topic_score_gemma":0.001049441,"domain_scores_codex":[0.9998398,0.00006526912,0.000009290915,0.00002693101,0.00002140568,0.00003725951],"domain_scores_gemma":[0.9997529,0.00003820568,0.00006791219,0.00001417975,0.00001762218,0.0001091255],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7467422,0.02467925,0.002564604,0.001154019,0.0007589555,0.0002989322,0.0001149482,0.001080124,0.06825431,0.0002517379,0.004328202,0.1497727],"study_design_scores_gemma":[0.6361514,0.3367425,0.01695594,0.00009572074,0.0003572719,0.0003130401,0.00004281554,0.001672515,0.005914198,0.0001872411,0.001525821,0.00004160777],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941859,0.002979375,0.000361378,0.0002237037,0.00007017969,0.0005978717,0.0003995915,0.0001593256,0.001022653],"genre_scores_gemma":[0.9938507,0.001709647,0.000815975,0.0004204804,0.00008586241,0.0005071319,0.0006385754,0.00001546602,0.001956126],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003957121,"threshold_uncertainty_score":0.01323789,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02616147524920965,"score_gpt":0.3033942289263568,"score_spread":0.2772327536771471,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}